China fines Simcere unit $3.7M for substandard rabies shots

Chinese drug regulators slapped Simcere Pharmaceutical Group's Jiangsu Yanshen unit with a $3.75 million fine for producing substandard human rabies vaccine. Jiangsu Yanshen also will have to foot the bill to re-vaccinate patients at a cost of up to $3.37 million. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.